Study on Clinicopathological Features and Prognostic Factors of Multifocal Lung Cancer

LI Xue; MA Qi-zhi; LIU Ning; WANG Yong-sheng

doi:10.12182/20201160107

Volume 51 Issue 6

Nov. 2020

Turn off MathJax

Article Contents

Abstract

References

JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCES) > 2020 > 51(6): 866-872. > DOI: 10.12182/20201160107

LI Xue, MA Qi-zhi, LIU Ning, et al. Study on Clinicopathological Features and Prognostic Factors of Multifocal Lung Cancer[J]. Journal of Sichuan University (Medical Sciences), 2020, 51(6): 866-872. DOI: 10.12182/20201160107

Citation:

PDF (579 KB)

Study on Clinicopathological Features and Prognostic Factors of Multifocal Lung Cancer

Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu 610041, China

More Information

Corresponding author:
WANG Yong-sheng, E-mail: wangys@scu.edu.cn
Received Date: March 15, 2020
Revised Date: August 26, 2020
Available Online: November 19, 2020
Published Date: November 19, 2020

Abstract

Abstract

Objective To analyze the clinicopathological characteristics and prognostic factors of multifocal lung cancer (MFLC) patients.
Methods From January 2012 to January 2018, 187 MFLC patients whose largest lesion diameter was ≤4 cm and without lymphatic involvement or systemic metastases, were retrospectively reviewed. All the patients received surgical treatment. The Kaplan-Meier method was used for survival analysis, and a multivariable Cox proportional hazards regression model was used to assess the independent prognostic factors.
Results Among 187 cases, 173 were simultaneous MFLC (SMFLC) and 14 were metachronous MFLC (MMFLC). The 5-year disease-free survival (DFS) and overall survival (OS) rates of this group MFLC patients were 63.5% and 89.1%, respectively. In the SMFLC group, according to the American College of Chest Physicians (ACCP) guidelines (3^rd edition), 133 patients were defined as synchronous multiple primary lung cancer (SMPLC) while 40 patients had intrapulmonary metastases, there was no statistical difference in DFS between the two subgroups (P=0.531). EGFR mutation status (same mutations, different mutations, all wild-type) had no statistically significant effect on DFS of SMFLC (P=0.388). Univariate and multivariate regression analysis revealed that radiographic feature of solid nodules (hazard ratio (HR)=7.4, P=0.008) and MMFLC (HR=5.6, P=0.001) were independent risk factors for poor prognosis.
Conclusion MFLC can achieve a favorable prognosis with early surgical treatment. Tumor density and metachronous lesions are two important prognostic predictors.
- Multiple primary lung cancer,
- Clinicopathological features,
- Prognosis

FullText(HTML)

References (29)

References

[1]	CORTES J, PEREZ-GARCÍA J M, LLOMBART-CUSSAC A, et al. Enhancing global access to cancer medicines. CA Cancer J Clin,2020,70(2): 105–124. DOI: 10.3322/caac.21597
[2]	WARTH A, MACHER-GOEPPINGER S, MULEY T, et al. Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy. Eur Respir J,2012,39(6): 1437–1442. DOI: 10.1183/09031936.00105911
[3]	KOZOWER B D, LARNER J M, DETTERBECK F C, et al. Special treatment issues in non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013, 143(5 Suppl): e369S-e399S[2020-02-15]. https://doi.org/10.1378/chest.12-2362.
[4]	GOLDSTRAW P, CHANSKY K, CROWLEY J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol,2016,11(1): 39–51. DOI: 10.1016/j.jtho.2015.09.009
[5]	RAMI-PORTA R, ASAMURA H, TRAVIS W D, et al. Lung cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin,2017,67(2): 138–155. DOI: 10.3322/caac.21390
[6]	KANG X, ZHANG C, ZHOU H, et al. Multiple pulmonary resections for synchronous and metachronous lung cancer at two Chinese centers. Ann Thorac Surg,2020,109(3): 856–863. DOI: 10.1016/j.athoracsur.2019.09.088
[7]	郎杉, 孙军平, 王娟, 等. 多原发肺癌临床特点及预后分析. 解放军医学院学报,2016,37(5): 421–424. DOI: 10.3969/j.issn.2095-5227.2016.05.004
[8]	TANVETYANON T, FINLEY D, FABIAN T, et al. Prognostic factors for survival after complete resections of synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data. Ann Oncol,2013,24(4): 889–894. DOI: 10.1093/annonc/mds495
[9]	HATTORI A, MATSUNAGA T, TAKAMOCHI K, et al. Radiological classification of multiple lung cancers and the prognostic impact based on the presence of a ground glass opacity component on thin section computed tomography. Lung Cancer,2017,113: 7–13. DOI: 10.1016/j.lungcan.2017.09.001
[10]	GANTI A K, LOBERIZA F R, Jr, KESSINGER A. Association of positive family history with survival of patients with lung cancer. Lung Cancer,2009,63(1): 136–139. DOI: 10.1016/j.lungcan.2008.04.008
[11]	LIU Y Y, CHEN Y M, YEN S H, et al. Multiple primary malignancies involving lung cancer-clinical characteristics and prognosis. Lung Cancer,2002,35(2): 189–194. DOI: 10.1016/S0169-5002(01)00408-1
[12]	WANG H, HOU J, ZHANG G, et al. Clinical characteristics and prognostic analysis of multiple primary malignant neoplasms in patients with lung cancer. Cancer Gene Ther,2019,26(11/12): 419–426.
[13]	SHOJI F, YAMAZAKI K, MIURA N, et al. Postoperative management of multiple primary cancers associated with non-small cell lung cancer. Anticancer Res,2018,38(6): 3773–3778. DOI: 10.21873/anticanres.12660
[14]	CHEN K, CHEN W, CAI J, et al. Favorable prognosis and high discrepancy of genetic features in surgical patients with multiple primary lung cancers. J Thorac Cardiovasc Surg,2018,155(1): 371–379.e1. DOI: 10.1016/j.jtcvs.2017.08.141
[15]	HATTORI A, MATSUNAGA T, TAKAMOCHI K, et al. Locoregional recurrence after segmentectomy for clinical-T1aN0M0 radiologically solid non-small-cell lung carcinoma. Eur J Cardiothorac Surg,2017,51(3): 518–525.
[16]	MARTINI N, MELAMED M R. Multiple primary lung cancers. J Thorac Cardiovasc Surg,1975,70(4): 606–612. DOI: 10.1016/S0022-5223(19)40289-4
[17]	SHEN K R, MEYERS B F, LARNER J M, et al. Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest,2007,132(3 Suppl): 290S–305S. DOI: 10.1378/chest.07-1382
[18]	DETTERBECK F C, JONES D R, KERNSTINE K H, et al. Special treatment issues. Chest,2003,123(1): 244S–258S. DOI: 10.1378/chest.123.1_suppl.244S
[19]	EBERHARDT W E, MITCHELL A, CROWLEY J, et al. The IASLC lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol,2015,10(11): 1515–1522. DOI: 10.1097/JTO.0000000000000673
[20]	TAKAMOCHI K, OH S, MATSUOKA J, et al. Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-Ras. Lung Cancer,2012,75(3): 313–320. DOI: 10.1016/j.lungcan.2011.08.007
[21]	LIN M W, WU C T, KUO S W, et al. Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: implication for surgical treatment of an uncommon lung malignancy. Ann Surg Oncol,2014,21(8): 2555–2562. DOI: 10.1245/s10434-014-3642-5
[22]	WU C T, LIN M W, HSIEH M S, et al. New aspects of the clinicopathology and genetic profile of metachronous multiple lung cancers. Ann Surg,2014,259(5): 1018–1024. DOI: 10.1097/SLA.0000000000000385
[23]	ASMAR R, SONETT J R, SINGH G, et al. Use of oncogenic driver mutations in staging of multiple primary lung carcinomas: a single-center experience. J Thorac Oncol,2017,12(10): 1524–1535. DOI: 10.1016/j.jtho.2017.06.012
[24]	SHI Y, AU J S, THONGPRASERT S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non–small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol,2014,9(2): 154–162. DOI: 10.1097/JTO.0000000000000033
[25]	PATEL S B, KADI W, WALTS A E, et al. Next-generation sequencing: a novel approach to distinguish multifocal primary lung adenocarcinomas from intrapulmonary metastases. J Mol Diagn,2017,19(6): 870–880. DOI: 10.1016/j.jmoldx.2017.07.006
[26]	EGUREN-SANTAMARIA I, SANCHEZ-BAYONA R, PATINO-GARCIA A, et al. Targeted DNA sequencing for assessing clonality in multiple lung tumors: a new approach to an old dilemma. Lung Cancer,2018,122: 120–123. DOI: 10.1016/j.lungcan.2018.05.029
[27]	ROEPMAN P, HEUVEL A T, SCHEIDEL K C, et al. Added value of 50-gene panel sequencing to distinguish multiple primary lung cancers from pulmonary metastases—a systematic investigation. J Mol Diagn,2018,20(4): 436–445. DOI: 10.1016/j.jmoldx.2018.02.007
[28]	MA P, FU Y, CAI M C, et al. Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nat Commun, 2017, 8(1): 823[2020-02-20]. https://www.nature.com/articles/s41467-017-00963-0. doi: 10.1038/s41467-017-00963-0.
[29]	LIU Y, ZHANG J, LI L, et al. Genomic heterogeneity of multiple synchronous lung cancer. Nat Commun, 2016, 7: 13200[2020-02-20]. https://doi.org/10.1038/ncomms13200.

Relative Articles

Supplements (0)

Cited By

Get Citation

PDF

XML

Article views (3494) PDF downloads (68)

Study on Clinicopathological Features and Prognostic Factors of Multifocal Lung Cancer

Abstract

References

Catalog

Export File

Citation

Format

Content